Bacteriophages have been used therapeutically to treat infectious bacterial diseases for over a century. As ...

Explore the potential of bacteriophages as a breakthrough therapy against bacterial infections amidst rising antibiotic ...

New collaboration empowers customers with sequence-perfect constructs as long as 50 kb Integrated DNA Technologies (IDT), a Danaher company and a global leader in genomics, and Ansa Biotechnologies, ...

Integrated DNA Technologies collaborates with Ansa Biotechnologies to expand capabilities to IDT’s synthetic biology portfolio: Sunnyvale Saturday, January 17, 2026, 14:00 Hrs [ ...

Scientists first read the human genome, a three-billion-letter biological book, in April 2003. Since then, researchers have steadily advanced the ability to write DNA, moving far beyond single-gene ...

Artis BioSolutions ("Artis"), a San Diego-based advanced-therapies development and manufacturing company, today announced ...

Modern DNA synthesis platforms empower researchers to explore the molecular world, from next-generation sequencing to cell and gene therapy development. Recent technological and scientific advances ...

Last year, during the Global Synthetic Biology (SynBioBeta) conference, Ansa Biotechnologies’ CEO Jason Gammack introduced attendees to the company’s first product—600 bp synthetic DNA constructs.

Researchers at UT Southwestern Medical Center have identified synthetic RNA and DNA that reverses the protein deficiency causing Friedreich's ataxia, a neurological disease for which there is ...

DNA is the raw material of modern medicine yet is the only part of drug development not accessible at the lab bench. DNA synthesis, the first step in most biological workflows including gene synthesis ...